A Phase 1 interventional study of Clenbuterol in Muscular Dystrophy, Facioscapulohumeral, sponsored by Jeffrey Statland. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-25.
Sponsored by Jeffrey Statland · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States — 8 open to participants now, 13 under way, 1 of them phase 3. Muscular Dystrophy, Facioscapulohumeral · United States.
Among the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States, this one is the 13th largest by planned enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2025, is one of 3 in phase 1, reaches primary completion later than 4 of the 12 other live ones, and was the 25th registered.
79 studies on the registry are indexed under Muscular Dystrophy, Facioscapulohumeral; 26 are open to participants now.
Browse Muscular Dystrophy, Facioscapulohumeral studies →8 of the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States are open now. Recruiting first, the newest first:
Scholar Rock, Inc. · Sites in United States
Ages 18–60
Restem, LLC. · Sites in United States
Ages 15+
Avidity Biosciences, Inc. · Sites in United States, Canada, Denmark and 7 more countries
Ages 16–70
University of Kansas Medical Center · Sites in United States, Australia
Ages 5–17
FSHD Society · Sites in United States
Ages 1+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 19 Muscular Dystrophy, Facioscapulohumeral studies recruiting now, 9 (47%) set no upper age limit and 9 (47%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 15 · Phase 3 2
First in 2000; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 48 across 49 interventional studies indexed under Muscular Dystrophy, Facioscapulohumeral.
Median enrollment 51 across the 21 interventional studies, 94 across the 11 observational. Of the 19 that completed or were terminated, 12 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 32 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Jeffrey Statland as lead sponsor.
Jeffrey Statland has 1 study filed under Muscular Dystrophy, Facioscapulohumeral — fewer than ten, so there is no comparison to draw.
3 of the studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06847282University of Kansas Medical CenterMotor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds) | 2027-05 |
| NCT05019625Massachusetts General HospitalBiomarker Development for Muscular Dystrophies | 2027-06 |
| NCT06907875Epicrispr Biotechnologies, Inc.A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy | 2027-07-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies in Muscular Dystrophy, Facioscapulohumeral with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if Clenbuterol is a therapeutic option for FSHD by determining the safety and tolerability of the medication at three different dose levels.
Clenbuterol is an EMA approved drug for COPD that three independent patient derived screens identified as suppressing DUX4 expression in cultured FSHD muscle. Prior clinical studies with related beta2-agonists showed some activity in FSHD but did not meet their primary endpoint, although the prior studies would likely have been designed differently with current knowledge. Target FSHD is a 6-month open-label multiple ascending dose study of clenbuterol for safety and tolerability to determine the best dose for a future trial of efficacy. In addition, this study will collect secondary outcome data on muscle function, MRI changes (lean muscle volume, fat infiltration, STIR-rating) and molecular markers of disease activity (histopathology and pre-determined baskets of DUX4-target, inflammation, and ECM genes) at the beginning and end of the study to assess and power their utility as measures of drug activity in a future interventional study of efficacy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
20 mcg taken orally twice daily
Drug: Clenbuterol
40 mcg taken orally twice daily
Drug: Clenbuterol
60 mcg taken orally twice daily
Drug: Clenbuterol
Beta-Agonist
Frequency of Clenbuterol-related adverse reactions
Patient report and medical records will be used to document adverse events and severe adverse events. Adverse events and severe adverse events will be assessed by the investigator and reported as needed for safety.
Time frame: from baseline to 6 month visit
change in heart rate
Review of Vitals
Time frame: from Month 1 to Month 6 visit
change in blood pressure
Review of Vitals
Time frame: from Month 1 to Month 6 visit
Safety Lab Potassium (K)
patient safety measured by potassium for signs of hypokalemia
Time frame: Baseline to month 6 visit
Safety Lab Glucose
Patient safety measured by blood glucose abnormalities
Time frame: Baseline to month 6 visit
Tolerability of 3 doses of clenbuterol in sequential cohorts
Tolerability will be defined as completing an arm without any clenbuterol related adverse events causing someone to withdraw
Time frame: from baseline to 6 month visit
Safety ECG
Looking for sympathomimetic side effects such as cardiac arrhythmias
Time frame: from Month 1 to Month 6 visit
Safety Lab Creatine kinase (CK)
Patient Safety measured by creatine kinase abnormalities
Time frame: Baseline to Month 6 visit
MRI
MRI measurements are considered gold standard for lean muscle volume measurement and disease biomarkers (fat volumes, fat faction, and STIR+ presence) that may be modulated by treatment. In addition, we will include analysis to help make needle biopsy based on STIR and quantitative fat fraction more efficient with higher yield using standard fiducial markings and body landmarks.
Time frame: Screening to Month 6 Visit
Muscle Biopsy for RNA sequencing
change in a set of DUX4-regulated genes as measured in muscle using RNA sequencing. goal is to better understand the molecular changes in muscle tissue effected by the use of Clenbuterol.
Time frame: Baseline and Month 6
FSHD-COM
An 18-item evaluator administered instrument comprised of individually validated functional motor task.the body regions assessed match areas of importance identified by patients and include leg function; shoulder and arm function; trunk function, hand function; and functional balance
Time frame: Screening to Month 6 Visit
Manual Muscle Testing (MMT)
a modified Medical Research Council 13-point scale with standardized positions for each muscle will help look at subject's change in strength over time.
Time frame: Screening to Month 6 Visit
Quantitative Muscle Testing (QMT)
Will test 5 bilateral muscles using a fixed myometry testing system with a force transducer attached by an inelastic strap to a metal frame, This will help us assess subjects change in strength
Time frame: Screening to Month 6 Visit
Patient Reported Outcome Measurement Information System-57 (Promis57)
The PROMIS57 is an instrument developed by the NIH which generates scores for physical function, and the impact of physical limitations on daily life. 57 questions are summed into a total score, which is transformed into a normalized t-score with 50 representing normal, and lower scores representing increasing disability.
Time frame: Screening to Month 6 Visit
FSHD Rasch-built overall disability scale (FSHD-RODS)
The FSHD-RODS is a questionnaire about the relationship between daily activities and health. 32 questions are are constructed using a modern clinimetric technique, the Rasch analysis, which by ordering the items in increasing difficulty, allows for the calculation of the sum of item scores to achieve a total score. Answers provide information about how FSHD affects daily and social activities and to what degree participants are able to perform usual activities.
Time frame: Screening to Month 6 Visit
Upper Extremity Functional Index (UEFI)
This index measures upper extremity dysfunction. 20 questions are combined into a total score, the score is transformed into a normalized score with 80 representing normal, and lower scores representing increasing disability.
Time frame: Screening to Month 6 visit
Clinical Global Impression of Severity and Change (CGI-S and CGI-C)
Is a rating scale that measures symptom severity and change in severity in response to treatment in clinical trials.
Time frame: Screening to Month 6 visit
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Feb 2028, 32 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clenbuterol
Muscular Dystrophy, Facioscapulohumeral →